This result confirms the feasibility of NKG2D-CAR expression from autologous NKAE cells and demonstrates that these autologous CAR-NKAE cells possess enhanced anti-myeloma activity, which supports further research and development of NKG2D-CAR-NK cells for the treatment of MM. This evidence concerns the gene KLRK1 and plasma cell myeloma.